Comparative Evaluation of STEAP1 Targeting Chimeric Antigen Receptors with Different Costimulatory Domains and Spacers

被引:2
|
作者
Jin, Yixin [1 ]
Dunn, Claire [1 ]
Persiconi, Irene [1 ]
Sike, Adam [1 ]
Skorstad, Gjertrud [2 ]
Beck, Carole [1 ]
Kyte, Jon Amund [1 ,2 ,3 ]
机构
[1] Oslo Univ Hosp, Inst Canc Res, Dept Canc Immunol, N-0379 Oslo, Norway
[2] Oslo Univ Hosp, Dept Clin Canc Res, N-0424 Oslo, Norway
[3] Oslo Metropolitan Univ, Fac Hlth Sci, N-0130 Oslo, Norway
关键词
chimeric antigen receptor; STEAP1; costimulatory domain; CAR spacer; 4-1BB; CD28; cell therapy; prostate cancer; xenograft mouse model; T cell phenotype; T-CELLS; IMMUNOTHERAPY; THERAPY;
D O I
10.3390/ijms25010586
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
We have developed a chimeric antigen receptor (CAR) against the six-transmembrane epithelial antigen of prostate-1 (STEAP1), which is expressed in prostate cancer, Ewing sarcoma, and other malignancies. In the present study, we investigated the effect of substituting costimulatory domains and spacers in this STEAP1 CAR. We cloned four CAR constructs with either CD28 or 4-1BB costimulatory domains, combined with a CD8a-spacer (sp) or a mutated IgG-spacer. The CAR T-cells were evaluated in short- and long-term in vitro T-cell assays, measuring cytokine production, tumor cell killing, and CAR T-cell expansion and phenotype. A xenograft mouse model of prostate cancer was used for in vivo comparison. All four CAR constructs conferred CD4+ and CD8+ T cells with STEAP1-specific functionality. A CD8sp_41BBz construct and an IgGsp_CD28z construct were selected for a more extensive comparison. The IgGsp_CD28z CAR gave stronger cytokine responses and killing in overnight caspase assays. However, the 41BB-containing CAR mediated more killing (IncuCyte) over one week. Upon six repeated stimulations, the CD8sp_41BBz CAR T cells showed superior expansion and lower expression of exhaustion markers (PD1, LAG3, TIGIT, TIM3, and CD25). In vivo, both the CAR T variants had comparable anti-tumor activity, but persisting CAR T-cells in tumors were only detected for the 41BBz variant. In conclusion, the CD8sp_41BBz STEAP1 CAR T cells had superior expansion and survival in vitro and in vivo, compared to the IgGsp_CD28z counterpart, and a less exhausted phenotype upon repeated antigen exposure. Such persistence may be important for clinical efficacy.
引用
收藏
页数:18
相关论文
共 28 条
  • [21] T-Cell immunotherapy for B-lineage acute lymphoblastic leukemia using chimeric antigen receptors that deliver 4-1BB-mediated costimulatory signals.
    Imai, C
    Mihara, K
    Andreansky, M
    Geiger, TL
    Campana, D
    BLOOD, 2003, 102 (11) : 66A - 67A
  • [22] Redirecting Specificity of T cells Using the Sleeping Beauty System to Express Chimeric Antigen Receptors by Mix-and-Matching of VL and VH Domains Targeting CD123+ Tumors
    Thokala, Radhika
    Olivares, Simon
    Mi, Tiejuan
    Maiti, Sourindra
    Deniger, Drew
    Huls, Helen
    Torikai, Hiroki
    Singh, Harjeet
    Champlin, Richard E.
    Laskowski, Tamara
    McNamara, George
    Cooper, Laurence J. N.
    PLOS ONE, 2016, 11 (08):
  • [23] Plasmodium vivax apical membrane antigen-1: comparative recognition of different domains by antibodies induced during natural human infection
    Mufalo, Bruno C.
    Gentil, Fernanda
    Bargieri, Daniel Y.
    Costa, Fabio T. M.
    Rodrigues, Mauricio M.
    Soares, Irene S.
    MICROBES AND INFECTION, 2008, 10 (12-13) : 1266 - 1273
  • [24] The ligand-selective domains of corticotropin-releasing factor type 1 and type 2 receptor reside in different extracellular domains: Generation of chimeric receptors with a novel ligand-selective profile
    Dautzenberg, FM
    Kilpatrick, GJ
    Wille, S
    Hauger, RL
    JOURNAL OF NEUROCHEMISTRY, 1999, 73 (02) : 821 - 829
  • [25] DNAM1 and 2B4 Costimulatory Domains Enhance the Cytotoxicity of Anti-GPC3 Chimeric Antigen Receptor-Modified Natural Killer Cells Against Hepatocellular Cancer Cells in vitro
    Huang, Yao
    Zeng, Jianxing
    Liu, Teng
    Xu, Qingyi
    Song, Xianglin
    Zeng, Jinhua
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 3247 - 3255
  • [26] Phase I Trial Results Testing Adoptively Transferred T Cells Expressing CD20-Specific Chimeric Antigen Receptors Containing CD28 and CD137 Costimulatory Domains In Patients with Mantle Cell Lymphoma and Indolent Lymphoma
    Till, Brian G.
    Jensen, Michael C.
    Qian, Xiaojun
    Wang, Jinjuan
    Gopal, Ajay K.
    Maloney, David G.
    Lindgren, Catherine G.
    Lin, Yukang
    Pagel, John M.
    Budde, Lihua E.
    Raubitschek, Andrew
    Forman, Stephen
    Greenberg, Philip
    Riddell, Stanley R.
    Press, Oliver W.
    BLOOD, 2010, 116 (21) : 248 - 249
  • [27] Sleeping Beauty Transposition of Chimeric Antigen Receptors Targeting Receptor Tyrosine Kinase-Like Orphan Receptor-1 (ROR1) into Diverse Memory T-Cell Populations
    Deniger, Drew C.
    Yu, Jianqiang
    Huls, M. Helen
    Figliola, Matthew J.
    Mi, Tiejuan
    Maiti, Sourindra N.
    Widhopf, George F.
    Hurton, Lenka V.
    Thokala, Radhika
    Singh, Harjeet
    Olivares, Simon
    Champlin, Richard E.
    Wierda, William G.
    Kipps, Thomas J.
    Cooper, Laurence J. N.
    PLOS ONE, 2015, 10 (06):
  • [28] Chimeric Antigen Receptors Combining 4-1BB and CD28 Signaling Domains Augment PI3kinase/AKT/Bcl-XL Activation and CD8+ T Cell-mediated Tumor Eradication
    Zhong, Xiao-Song
    Matsushita, Maiko
    Plotkin, Jason
    Riviere, Isabelle
    Sadelain, Michel
    MOLECULAR THERAPY, 2010, 18 (02) : 413 - 420